Generic drug: bosutinib
Brand name: Bosulif
What is Bosulif (bosutinib), and how does it work?
Bosulif (bosutinib) is a prescription medicine used to treat adults who have a certain type of leukemia called Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML) who are newly-diagnosed or who no longer benefit from or did not tolerate other treatment.
It is not known if Bosulif is safe and effective in children less than 18 years of age.
What are the side effects of Bosulif?
Bosulif may cause serious side effects, including:
- Stomach problems. Bosulif may cause stomach (abdomen) pain, nausea, diarrhea, vomiting, or blood in your stools. Get medical help right away for any stomach problems.
- Low blood cell counts. Bosulif may cause low platelet counts (thrombocytopenia), low red blood cell counts (anemia) and low white blood cell counts (neutropenia). Your doctor should do blood tests to check your blood cell counts regularly during your treatment with Bosulif. Call your doctor right away if you have unexpected bleeding or bruising, blood in your urine or stools, fever, or any signs of an infection.
- Liver problems. Bosulif may cause liver problems. Your doctor should do blood tests to check your liver function regularly during your treatment with Bosulif. Call your doctor right away if your skin or the white part of your eyes turns yellow (jaundice) or you have dark “tea color” urine.
- Heart problems. Bosulif may cause heart problems, including heart failure. Get medical help right away if you get shortness of breath, weight gain or swelling in your hands, ankles or feet.
- Your body may hold too much fluid (fluid retention). Fluid may build up in the lining of your lungs, the sac around your heart, or your stomach cavity. Get medical help right away if you get any of the following symptoms during your treatment with Bosulif:
- Kidney problems. Bosulif may cause kidney problems. Your doctor should do tests to check your kidney function when you start treatment with
Bosulif and during your treatment. Call your doctor right away if you get any of the following symptoms during your treatment with
- you urinate more often than normal
- you urinate less often than normal
- you make a much larger amount of urine than normal
- you make a much smaller amount of urine than normal
The most common side effects of Bosulif in people with newly-diagnosed CML include:
The most common side effects of Bosulif in people with CML who no longer benefit from or did not tolerateother treatment include:
- stomach (abdomen) pain
- low platelet counts
- change in liver function test
- low red blood cell counts
Tell your doctor or get medical help right away if you get respiratory tract infections, loss of appetite, headache,dizziness, back pain, joint pain, or itching while taking Bosulif. These may be symptoms of a severe allergic reaction.
Your doctor may change your dose, temporarily stop, or permanently stop treatment with Bosulif if you have certain side effects.
Bosulif may cause fertility problems in females and males. This may affect your ability to have a child. Talk toyour doctor if this is a concern for you.
Tell your doctor if you have any side effect that bothers you or that does not go away.
These are not all of the possible side effects of Bosulif. For more information, ask your doctor or pharmacist.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is the dosage for Bosulif?
The recommended dose is taken orally once daily with food. The tablet is to be swallowed whole and should not be broken or cut. Continue treatment with Bosulif until disease progression or intolerance to therapy.
If a dose is missed beyond 12 hours, the patient should skip the dose and take the usual prescribed dose on the following day.
Newly-Diagnosed CP Ph+ CML
- The recommended dose of Bosulif is 400 mg orally once daily with food.
CP, AP, Or BP Ph+ CML With Resistance Or Intolerance To Prior Therapy
- The recommended dose and schedule of Bosulif is 500 mg orally once daily with food.
- In clinical studies of adult Ph+ CML patients, dose escalation by increments of 100 mg once daily to a maximum of 600 mg once daily was allowed in patients who did not achieve or maintain a hematologic, cytogenetic, or molecular response and who did not have Grade 3 or higher adverse reactions at the recommended starting dosage.
Dose Adjustments For Non-Hematologic Adverse Reactions
- Elevated liver transaminases: If elevations in liver transaminases greater than 5xinstitutional upper limit of normal (ULN) occur, withhold Bosulif until recovery to less than or equal to 2.5xULN and resume at 400 mg once daily thereafter.
- If recovery takes longer than 4 weeks, discontinue Bosulif. If transaminase elevations greater than or equal to 3xULN occur concurrently with bilirubin elevations greater than 2xULN and alkaline phosphatase less than 2xULN (Hy's law case definition), discontinue Bosulif.
- For National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Grade 3-4 diarrhea (increase of greater than or equal to 7 stools/day over baseline/pretreatment), withhold Bosulif until recovery to Grade less than or equal to 1. Bosulif may be resumed at 400 mg once daily.
- For other clinically significant, moderate or severe non-hematological toxicity, withhold Bosulif until the toxicity has resolved, then consider resuming Bosulif at a dose reduced by 100 mg taken once daily. If clinically appropriate, consider re-escalating the dose of Bosulif to the starting dose taken once daily. Doses less than 300 mg/day have been used in patients; however, efficacy has not been established.
Dose Adjustments For Myelosuppression
Table 1: Dose Adjustments for Neutropenia and Thrombocytopenia
|ANCa less than 1000 x 106/L or Platelets less than 50,000* 106/L||Withhold Bosulif until ANC greater than or equal to1000*106/L and platelets greater than or equal to 50,000*106/L.
Resume treatment with Bosulif at the same dose if recovery occurs within 2 weeks. If blood counts remain low for greater than 2 weeks, upon recovery, reduce dose by 100 mg and resume treatment.
If cytopenia recurs, reduce dose by an additional 100 mg upon recovery and resume treatment.
Doses less than 300 mg/day have been used in patients; however, efficacy has not been established.
|a Absolute Neutrophil Count|
Dose Adjustments For Renal Impairment Or Hepatic Impairment
The recommended starting doses for patients with renal and hepatic impairment are described in Table 2 below.
Table 2: Dose Adjustments for Renal and Hepatic Impairment
|Recommended Starting Dosage|
|Newly-diagnosed chronic phase Ph+ CML2||Chronic, accelerated, or blast phase Ph+ CML with resistance or intolerance to prior therapy|
|Normal renal and hepatic function||400 mg daily||500 mg daily|
|Creatinine clearance 30 to 50 mL/min||300 mg daily||400 mg daily|
|Creatinine clearance less than 30 mL/min||200 mg daily||300 mg daily|
|Mild (Child-Pugh A), Moderate (Child-Pugh B) or Severe (Child-Pugh C)||200 mg dailya||200 mg dailya|
|Abbreviations: CML=chronic myelogenous leukemia; Ph+=Philadelphia chromosome-positive.
a There are no clinical data for efficacy at the dose of 200 mg once daily in patients with CML.
What drugs interact with Bosulif?
Effect Of Other Drugs On Bosulif
Strong Or Moderate CYP3A Inhibitors
- Concomitant use with a strong or moderate CYP3A inhibitor increased bosutinib Cmax and AUC compared to Bosulif alone which may increase the risk of toxicities. Avoid the concomitant use of strong or moderate CYP3A inhibitors with Bosulif.
Strong CYP3A Inducers
- Concomitant use with a strong CYP3A inducer decreased bosutinib Cmax and AUC compared to Bosulif alone which may reduce Bosulif efficacy. Avoid the concomitant use of strong CYP3A inducers with Bosulif.
Proton Pump Inhibitors (PPI)
- Concomitant use with a PPI decreased bosutinib Cmax and AUC compared to Bosulif alone which may reduce Bosulif efficacy. As an alternative to PPIs, use short-acting antacids or H2 blockers and separate dosing by more than 2 hours from Bosulif dosing.
Is Bosulif safe to use while pregnant or breastfeeding?
- Based on findings from animal studies and its mechanism of action, Bosulif can cause fetal harm when administered to a pregnant woman.
- There are no available data in pregnant women to inform the drug-associated risk.
- No data are available regarding the presence of bosutinib or its metabolites in human milk or its effects on a breastfed child or on milk production.
- Because of the potential for serious adverse reactions in a nursing child, breastfeeding is not recommended during treatment with Bosulif and for at least 2 weeks after the last dose.
Latest Cancer News
- Breast Cancer Patients Who Can Skip Post-Op Chemo
- Evidence That Pandemic Delayed Cancer Diagnosis
- Do Immune-Based Cancer Drugs Work Better in Men?
- HPV Vaccine Is Reducing Cervical Cancers in Teens
- Old Spice, Secret Products Recalled Due to Benzene
- Want More News? Sign Up for MedicineNet Newsletters!
Daily Health News
Multimedia: Slideshows, Images & Quizzes
Blood Cancer Types: Leukemia, Lymphomas, Myelomas, and More
Types of blood cancers include leukemia, lymphomas, multiple myelomas, and others discussed in this slideshow. Symptoms may...
Cancer: Guide to Leukemia
Learn about the common types and stages of leukemia, who gets it, symptoms, tests, treatments, and more. People with blood cancer...
What do you know about leukemia? Did you know there are different types? What are the symptoms? Take the Leukemia Quiz and test...
Related Disease Conditions
Cancer is a disease caused by an abnormal growth of cells, also called malignancy. It is a group of 100 different diseases, and is not contagious. Cancer can be treated through chemotherapy, a treatment of drugs that destroy cancer cells.
Cancer Risk Factors and Causes
Though it's difficult to say why some people develop cancer while others don't, research shows that certain risk factors increase a person's odds of developing cancer. These risk factors include growing older, family history of cancer, diet, alcohol and tobacco use, and exposure to sunlight, ionizing radiation, certain chemicals, and some viruses and bacteria.
What Is the Life Expectancy of a Person With Leukemia?
Leukemia is a group of cancers of the blood affecting the white blood cells. White blood cells are the infection-fighting cells of the body. In adults, leukemia is most common in people older than 55 years, with the average age of diagnosis being 66 years. It is also one of the most common cancers in children and adults younger than 20 years. The survival rate is higher for younger people.
Leukemia is a type of cancer of the blood cells in which the growth and development of the blood cells are abnormal. Strictly speaking, leukemia should refer only to cancer of the white blood cells (the leukocytes) but in practice it can apply to malignancy of any cellular element in the blood or bone marrow, as in red cell leukemia (erythroleukemia).
Second Source article from Government
How Does Leukemia Kill?
Leukemia is a cancer of the white blood cells of the bone marrow. Patients with leukemia have an over-production of a particular blood cell type in the body, the white blood cells (cells that fight infection, and provide immunity).
Survival Rate for Acute Lymphoblastic Leukemia
The prognosis depends on the type of leukemia, the extent of the disease, age of the patient, and the general condition of the patient. Some patients can go into complete remission. The average five-year survival rate of leukemia is 60-65%.
Leukemia: Signs, Symptoms, And Complications
Leukemia results when the genetic material (DNA) of a single cell in the bone marrow transforms, this is called a mutation. A mutated cell does not perform body function, but it eats away the nutrition meant for the normal cells.
Certain behavioral, lifestyle, and environmental factors contribute to cancer. Cancer prevention involves modifying these factors to decrease cancer risk. Tobacco use, alcohol consumption, physical inactivity, inadequate fruit and vegetable intake, and obesity increase the risk of certain cancers. Vaccines, genetic testing, and cancer screening also play a role in cancer prevention.
Childhood Acute Lymphoblastic Leukemia (ALL)
Childhood acute lymphoblastic leukemia is the most common type of cancer in children. Symptoms and signs include fever, easy bruising, bone or joint pain, weakness, loss of appetite, and painless lumps in the neck, underarm, stomach, or groin. Treatment depends upon staging and may include chemotherapy, radiation, or stem cell transplant.
What Are the Stages of Chronic Lymphocytic Leukemia?
Chronic lymphocytic leukemia is a cancer of the blood and bone marrow. With this type of cancer, the marrow creates too many abnormal lymphocytes. There are five stages of chronic lymphocytic leukemia.
Treatment & Diagnosis
- Leukemia FAQs
- Evolution of Treatment for a Rare Type of Leukemia
- Gleevec and Chronic Myeloid Leukemia
- How Familes Cope with a Leukemia Diagnosis
- Coping with a Bad Disease - Community Counts
- A Family's Leukemia Diary - Coping
- Is Multiple Myeloma the Same as Leukemia?
- Does Folic Acid Prevent Leukemia?
- Can Folic Acid Prevent Leukemia?
- Chronic Myelogenous Leukemia (CML)
Medications & Supplements
Health Solutions From Our Sponsors
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.